Cargando…

The potential role of HER2 upregulation in metastatic breast cancer to the uterus: a case report

Abnormal uterine bleeding in a patient on maintenance hormonal therapy for breast cancer should raise concern for endometrial abnormalities including rare uterine metastasis from the breast. Hormonal receptor profile changes in metastatic lesions favoring human epidermal growth factor receptor 2 (HE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moey, Melissa Y. Y., Hassan, Omer A., Papageorgiou, Christos N., Schnepp, Stephanie L., Hoff, John T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054465/ https://www.ncbi.nlm.nih.gov/pubmed/27761241 http://dx.doi.org/10.1002/ccr3.602

Ejemplares similares

From anemia to polycythemia in 4 weeks
por: Hassan, Omer A., et al.
Publicado: (2017)

Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study
por: Moey, Melissa Y. Y., et al.
Publicado: (2019)

Palliative hysterectomy for vaginal bleeding from breast cancer metastatic to the uterus
por: Berger, Amnon A, et al.
Publicado: (2018)

Metastatic HER2+ Breast Cancer: A Potentially Curable Disease?
por: Prior, Lisa, et al.
Publicado: (2017)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
por: Dent, S., et al.
Publicado: (2009)

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
por: Park, Y H, et al.
Publicado: (2014)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
por: Tsang, R Y, et al.
Publicado: (2012)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
por: Colomer, R., et al.
Publicado: (2017)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
por: Li, Xin, et al.
Publicado: (2018)

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
por: Tokuda, Y, et al.
Publicado: (1999)

Late presentation of metastatic smooth muscle neoplasm of the uterus with low malignant potential
por: Canciani, Gioia N., et al.
Publicado: (2012)

Venous varices of the heart: a case report of spontaneous coronary sinus thrombosis with persistent left superior vena cava
por: Moey, Melissa Y Y, et al.
Publicado: (2018)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Pizzuti, Laura, et al.
Publicado: (2021)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor()
por: Beije, Nick, et al.
Publicado: (2016)

HER2 upregulates fatty acid synthase and acetyl-CoA carboxylase at a translational level in breast cancer cells
por: Yoon, S, et al.
Publicado: (2005)

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
por: Arai, Roberto J., et al.
Publicado: (2018)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer
por: Chandran, Vineesh Indira, et al.
Publicado: (2015)

A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells
por: Chu, B, et al.
Publicado: (2015)

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
por: Yu, Y. F., et al.
Publicado: (2017)

Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature
por: Ge, Jennifer Y., et al.
Publicado: (2021)

Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer
por: Park, Yeon Hee, et al.
Publicado: (2015)

TIMAP Upregulation Correlates Negatively with Survival in HER2- Negative Subtypes of Breast Cancer
por: Obeidat, Marya, et al.
Publicado: (2021)

Dehiscence and embolization of CorMatrix tricuspid valve replacement in the setting of infective endocarditis: a case report
por: Tomdio, Anna N, et al.
Publicado: (2018)

Large Left Ventricular Thrombus as a Cause of Recurrent Cardioembolic Stroke While on Dabigatran
por: Moey, Melissa Y.Y., et al.
Publicado: (2018)

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer
por: Toi, Masakazu, et al.
Publicado: (2010)

Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer
por: Chow, L W-C, et al.
Publicado: (2013)

Current approaches to the management of Her2-negative metastatic breast cancer
por: Gogineni, Keerthi, et al.
Publicado: (2012)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer
por: dos Santos, Giovana Tavares, et al.
Publicado: (2017)

ASCO 2018: highlights in HER2-positive metastatic breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2018)

Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2022)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer
por: Eli, Lisa D., et al.
Publicado: (2022)

Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer
por: Beasley, Marcie, et al.
Publicado: (2023)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer
por: Moilanen, Tiina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r37lqnujs2s0bavftl08q250pa